Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared

SG&A Spending: Dr. Reddy's vs. MannKind

__timestampDr. Reddy's Laboratories LimitedMannKind Corporation
Wednesday, January 1, 20143878300000079383000
Thursday, January 1, 201542585000000108402000
Friday, January 1, 20164570200000046928000
Sunday, January 1, 20174637200000074959000
Monday, January 1, 20184691000000079716000
Tuesday, January 1, 20194889000000074669000
Wednesday, January 1, 20205012900000059040000
Friday, January 1, 20215455900000077417000
Saturday, January 1, 20226208100000091473000
Sunday, January 1, 202310593100000094314000
Monday, January 1, 202477201000000
Loading chart...

Unleashing the power of data

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Dr. Reddy's Laboratories Limited, a major player in the industry, has shown a remarkable upward trend in SG&A expenses over the past decade. From 2014 to 2023, their spending surged by approximately 173%, peaking in 2023. This reflects their aggressive market expansion and investment in operational efficiencies.

In contrast, MannKind Corporation, a smaller entity, has maintained a more conservative approach. Their SG&A expenses have remained relatively stable, with a modest increase of around 19% over the same period. This cautious strategy might be indicative of their focus on niche markets and cost management.

The data for 2024 is incomplete, but the trends observed provide valuable insights into the strategic priorities of these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025